Arsenic causing gallbladder cancer disease in Bihar.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Arsenic*/analysis ; Gallbladder Neoplasms*/epidemiology ; Gallbladder Neoplasms*/etiology ; Arsenic Poisoning*/complications ; Arsenic Poisoning*/epidemiology ; Gallstones*/epidemiology; Humans ; Carcinogenesis ; India/epidemiology

In recent times Gallbladder cancer (GBC) incidences increased many folds in India and are being reported from arsenic hotspots identified in Bihar. The study aims to establish association between arsenic exposure and gallbladder carcinogenesis. In the present study, n = 200 were control volunteers and n = 152 confirmed gallbladder cancer cases. The studied GBC patient's biological samples-gallbladder tissue, gallbladder stone, bile, blood and hair samples were collected for arsenic estimation. Moreover, n = 512 gallbladder cancer patients blood samples were also evaluated for the presence of arsenic to understand exposure level in the population. A significantly high arsenic concentration (p < 0.05) was detected in the blood samples with maximum concentration 389 µg/L in GBC cases in comparison to control. Similarly, in the gallbladder cancer patients, there was significantly high arsenic concentration observed in gallbladder tissue with highest concentration of 2166 µg/kg, in gallbladder stones 635 µg/kg, in bile samples 483 µg/L and in hair samples 6980 µg/kg respectively. Moreover, the n = 512 gallbladder cancer patient's blood samples study revealed very significant arsenic concentration in the population of Bihar with maximum arsenic concentration as 746 µg/L. The raised arsenic concentration in the gallbladder cancer patients' biological samples-gallbladder tissue, gallbladder stone, bile, blood, and hair samples was significantly very high in the arsenic exposed area. The study denotes that the gallbladder disease burden is very high in the arsenic exposed area of Bihar. The findings do provide a strong link between arsenic contamination and increased gallbladder carcinogenesis.
(© 2023. The Author(s).)

Nat Genet. 2015 Sep;47(9):1003-10. (PMID: 26258846)
Metallomics. 2015 Jan;7(1):39-55. (PMID: 25356501)
Chem Res Toxicol. 2004 Dec;17(12):1733-42. (PMID: 15606151)
Cancer Res. 1990 Sep 1;50(17):5470-4. (PMID: 2386951)
HPB (Oxford). 2008;10(5):327-31. (PMID: 18982147)
J Nutr. 2007 Aug;137(8):1887-94. (PMID: 17634260)
Environ Health Perspect. 1977 Aug;19:109-19. (PMID: 908285)
BMJ. 1998 Nov 7;317(7168):1288-9. (PMID: 9804716)
HPB (Oxford). 2007;9(1):71-2. (PMID: 18333116)
Epidemiology. 2000 Nov;11(6):673-9. (PMID: 11055628)
HPB (Oxford). 2011 Feb;13(2):117-25. (PMID: 21241429)
Acta Trop. 2019 May;193:217-226. (PMID: 30857860)
World J Gastroenterol. 2009 Apr 21;15(15):1854-62. (PMID: 19370783)
Free Radic Biol Med. 2001 Aug 1;31(3):321-30. (PMID: 11461769)
J Surg Oncol. 2017 Apr;115(5):580-590. (PMID: 28138977)
Environ Sci Pollut Res Int. 2022 Apr;29(18):27443-27459. (PMID: 34982385)
J Environ Sci Health A Tox Hazard Subst Environ Eng. 2011;46(11):1177-84. (PMID: 21879850)
Oncotarget. 2016 Dec 6;7(49):80482-80492. (PMID: 27741521)
Sci Rep. 2017 Jul 14;7(1):5505. (PMID: 28710376)
Int J Cancer. 2006 Apr 1;118(7):1591-602. (PMID: 16397865)
Carcinogenesis. 2008 Sep;29(9):1831-6. (PMID: 18321869)
Nat Protoc. 2020 May;15(5):1829-1852. (PMID: 32269383)
Ann Hepatol. 2005 Jul-Sep;4(3):192-9. (PMID: 16177659)
Mol Cell Biochem. 2004 Jan;255(1-2):67-78. (PMID: 14971647)
Cancer Lett. 2009 Dec 1;286(1):29-37. (PMID: 19376640)
Curr Pharmacol Rep. 2016 Apr;2(2):57-63. (PMID: 27134817)
Regul Toxicol Pharmacol. 2018 Nov;99:78-88. (PMID: 30223072)
J Toxicol. 2011;2011:431287. (PMID: 22174709)
Epidemiol Rev. 1994;16(2):184-209. (PMID: 7713176)
Environ Sci Pollut Res Int. 2021 Aug;28(32):43923-43934. (PMID: 33840036)
Int J Cancer. 2020 May 1;146(9):2648-2650. (PMID: 31846055)
Ann Med Health Sci Res. 2014 Sep;4(Suppl 3):S329-31. (PMID: 25364614)
J Cancer Res Ther. 2019 Jan-Mar;15(1):153-156. (PMID: 30880772)
IARC Monogr Eval Carcinog Risks Hum. 2004;84:1-477. (PMID: 15645577)
J Natl Cancer Inst. 1980 Dec;65(6):1209-14. (PMID: 6933267)
Mutat Res. 1997 Jun;386(3):263-77. (PMID: 9219564)
Cancer Epidemiol Biomarkers Prev. 2021 Feb;30(2):396-403. (PMID: 33187967)
Biochim Biophys Acta. 2007 Jul;1770(7):1053-61. (PMID: 17451884)
Nucleic Acids Res. 2000 Jan 1;28(1):235-42. (PMID: 10592235)
Clin Epidemiol. 2014 Mar 07;6:99-109. (PMID: 24634588)
Chem Biol Interact. 2006 Mar 10;160(1):1-40. (PMID: 16430879)
Ann N Y Acad Sci. 2006 Sep;1076:810-21. (PMID: 17119258)
Chin Clin Oncol. 2019 Aug;8(4):31. (PMID: 31484487)
Cancer Sci. 2017 Oct;108(10):1927-1933. (PMID: 28776911)
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. (PMID: 21296855)
Lancet Oncol. 2003 Mar;4(3):167-76. (PMID: 12623362)
J Biol Chem. 2011 Jul 1;286(26):22855-63. (PMID: 21550982)
HPB (Oxford). 2013 Nov;15(11):839-44. (PMID: 23458506)
Indian J Gastroenterol. 1999 Jan-Mar;18(1):24-8. (PMID: 10063743)
ScientificWorldJournal. 2014;2014:304524. (PMID: 25374935)
Int J Cancer. 2010 Nov 15;127(10):2446-54. (PMID: 20473911)
Trop Gastroenterol. 2012 Jan-Mar;33(1):39-44. (PMID: 22803294)
Sci Rep. 2020 Mar 18;10(1):4915. (PMID: 32188916)
Toxicol Appl Pharmacol. 2004 Aug 1;198(3):243-52. (PMID: 15276403)
Mol Cell Biochem. 2002 May-Jun;234-235(1-2):301-8. (PMID: 12162448)
Cancer Res. 2006 Nov 15;66(22):10843-8. (PMID: 17108120)
Carcinogenesis. 2009 Jul;30(7):1073-81. (PMID: 19468060)
Asian Pac J Cancer Prev. 2012;13(1):187-90. (PMID: 22502665)
Mutat Res. 2006 Jun;612(3):215-246. (PMID: 16574468)
Sci Total Environ. 2012 Jul 1;429:2-35. (PMID: 21959248)
Medwave. 2015 Aug 31;15(7):e6239. (PMID: 26352152)
Protein Sci. 2021 Jan;30(1):70-82. (PMID: 32881101)
Dig Dis Sci. 2012 May;57(5):1163-70. (PMID: 22370917)
J Natl Cancer Inst. 2007 Jun 20;99(12):920-8. (PMID: 17565158)
Eur J Cancer Prev. 2003 Feb;12(1):15-24. (PMID: 12548106)
Cancers (Basel). 2021 May 28;13(11):. (PMID: 34071196)
Mutat Res. 2003 Dec 10;533(1-2):37-65. (PMID: 14643412)
Hepatology. 1996 Jun;23(6):1402-11. (PMID: 8675157)
Oncol Lett. 2018 Mar;15(3):4026-4032. (PMID: 29467911)
Semin Radiat Oncol. 2017 Apr;27(2):143-149. (PMID: 28325240)
Toxicol Sci. 2006 Mar;90(1):142-8. (PMID: 16322079)
Biochim Biophys Acta. 2016 Apr;1865(2):245-54. (PMID: 26980625)
Chem Rev. 2013 Oct 9;113(10):7769-92. (PMID: 23808632)
South Asian J Cancer. 2018 Jul-Sep;7(3):167-170. (PMID: 30112331)
Nat Rev Genet. 2008 Feb;9(2):102-14. (PMID: 18197166)
Nat Genet. 2014 Aug;46(8):872-6. (PMID: 24997986)
Toxicol Appl Pharmacol. 2001 May 1;172(3):249-61. (PMID: 11312654)
Int J Hyg Environ Health. 2002 Mar;205(1-2):85-94. (PMID: 12018020)
Chem Res Toxicol. 2017 Jul 17;30(7):1481-1491. (PMID: 28537708)
Ann Surg. 2014 Dec;260(6):1073-80. (PMID: 24827397)
Lancet Oncol. 2009 May;10(5):453-4. (PMID: 19418618)
BMC Cancer. 2018 Jun 18;18(1):665. (PMID: 29914418)
Food Chem. 2019 Mar 15;276:608-618. (PMID: 30409639)
Oncotarget. 2015 Sep 22;6(28):25646-59. (PMID: 26213848)
Environ Mol Mutagen. 2010 Jan;51(1):1-14. (PMID: 19551812)
J Hepatobiliary Pancreat Surg. 2007;14(4):366-73. (PMID: 17653634)
Carcinogenesis. 2008 Aug;29(8):1500-8. (PMID: 18448484)
Toxicol Sci. 2006 Jun;91(2):372-81. (PMID: 16543296)
Nature. 2013 Oct 17;502(7471):333-339. (PMID: 24132290)
J Pathol. 2009 Jan;217(2):161-8. (PMID: 18855879)
J Natl Cancer Inst. 2018 Mar 1;110(3):241-249. (PMID: 29069505)
Sci Rep. 2021 Jan 27;11(1):2376. (PMID: 33504854)
World J Gastroenterol. 2017 Jun 14;23(22):3978-3998. (PMID: 28652652)
J Trace Elem Med Biol. 2016 Dec;38:33-45. (PMID: 27238728)
Environ Monit Assess. 2005 Jun;105(1-3):43-67. (PMID: 15952511)
J Surg Oncol. 2006 Jun 15;93(8):615-23. (PMID: 16724345)
Am J Epidemiol. 2004 Feb 15;159(4):381-9. (PMID: 14769642)
Toxicol Sci. 2006 Feb;89(2):431-7. (PMID: 16251483)
Rev Med Chil. 2001 Oct;129(10):1113-20. (PMID: 11775337)
Nat Rev Cancer. 2014 May;14(5):359-70. (PMID: 24739573)
Asian Pac J Cancer Prev. 2011;12(2):387-91. (PMID: 21545200)
Toxicol Appl Pharmacol. 2008 Sep 1;231(2):142-9. (PMID: 18501398)
J Occup Health. 2015;57(2):161-8. (PMID: 25735624)
Drug Metab Rev. 2006;38(4):791-804. (PMID: 17145702)
Toxicol Sci. 2011 May;121(1):110-22. (PMID: 21292642)
Indian J Gastroenterol. 2009 Jul-Aug;28(4):126-30. (PMID: 19937419)
Arch Toxicol. 2008 Aug;82(8):493-512. (PMID: 18496671)
Nat Rev Cancer. 2006 Nov;6(11):857-66. (PMID: 17060945)
Toxicol Appl Pharmacol. 2005 Aug 15;206(3):288-98. (PMID: 16039940)
Int J Cancer. 2013 Apr 1;132(7):1660-6. (PMID: 22890893)
Science. 2008 Sep 26;321(5897):1801-6. (PMID: 18772397)
Am J Gastroenterol. 2002 May;97(5):1138-42. (PMID: 12014717)
Toxicology. 2002 Dec 27;181-182:211-7. (PMID: 12505313)
Toxicol Lett. 2003 Jan 31;137(1-2):3-13. (PMID: 12505428)
Lancet Oncol. 2016 Jul;17(7):e272. (PMID: 27237613)
Chin Clin Oncol. 2019 Aug;8(4):33. (PMID: 31484488)
Eur J Cancer Prev. 2020 Mar;29(2):100-109. (PMID: 31145133)
Lancet. 2012 Feb 18;379(9816):603. (PMID: 22355811)
PLoS One. 2010 Sep 07;5(9):e12602. (PMID: 20830294)
Carcinogenesis. 2003 Nov;24(11):1811-7. (PMID: 12919960)
Gastroenterol Hepatol (N Y). 2008 Oct;4(10):737-41. (PMID: 21960896)
Int J Dermatol. 2002 Dec;41(12):841-6. (PMID: 12492966)

N712M78A8G (Arsenic)

Date Created: 20230315 Date Completed: 20230316 Latest Revision: 20230420

20240513

PMC10014949

10.1038/s41598-023-30898-0

36918592